Form D · Pharmaceuticals

Presidio Pharmaceuticals, Inc.

San Francisco, CA · CIK 0001467435

Offering snapshot reported Jun 16, 2014 · SEC filing

Reported sold
$21.8M
Offering amount: $22.5M
Investors reported
16
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 5, 2013
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$10.9M$21.8MApr 17, 2013: $8,608,981.00Apr 17, 2013Jun 16, 2014: $21,827,981.00Jun 16, 2014

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$8,608,981 → $21,827,981
  • Reported investors9 → 16

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 16, 2014Amendment$21,827,981$13,219,000vs Apr 17, 201316SEC filing
Apr 17, 2013Initial$8,608,981No comparison9SEC filing
Nov 2, 2012Amendment$14,377,542$8,377,542vs Dec 20, 201121SEC filing
Dec 20, 2011Initial$6,000,000No comparison11SEC filing
Aug 5, 2011Initial$3,000,050No comparison11SEC filing
Jul 10, 2009Amendment$18,750,250$0vs Jul 10, 200911SEC filing
Jul 10, 2009Initial$18,750,250No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-195112
Series D Preferred Stock; Common Stock issuable upon conversion

Source: Form D, filed Jun 16, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Srinivas Akkaraju Director
H. Thomas Anderton Executive
Felix Baker Director
Nat Brown Executive
Nathaniel Brown Executive
Rich Colonno Executive
Richard Colonno Executive
Rodney Ferguson Director
Kenneth Galbraith Director
Omar Haffar Director
David Jobes Executive
Scott Lessing Director
Leping Li Executive
Kelvin Neu Director
John F. Obijeski Director
Jack Obijeski Director
H. Daniel Perez Director
Daniel Perez Director
Leo Redmond Director, Executive
Eric Ruby Executive
Pamela Vig Executive
Robert Williamson Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1700 Owens Street Suite 585
San Francisco, CA, 94158